Microscale purification of antigen-specific antibodies

Journal of Immunological Methods

Volumn 425, Issue , 2015, Pages 27-36

  Brown, Eric P ^a   Normandin, Erica ^a   Osei Owusu, Nana Yaw ^b   Mahan, Alison E ^c   Chan, Ying N ^a   Lai, Jennifer I ^a   Vaccari, Monica ^d   Rao, Mangala ^e   Franchini, Genoveffa ^d   Alter, Galit ^c   Ackerman, Margaret E ^a  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH COLLEGE   (United States)

^c HARVARD UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Antibody; Antigen; Effector function; Glycosylation; Purification

Indexed keywords

ANTIGEN; ANTIGEN P24; GLYCAN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B12; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; V2 LOOP PEPTIDE; VIRUS ANTIGEN; VIRUS PROTEIN; ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT;

ANTIBODY PURIFICATION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; PRIORITY JOURNAL; PURIFICATION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; IMMUNOLOGY; ISOLATION AND PURIFICATION;

ANTIBODIES; ANTIGENS; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G;

EID: 84943663283     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2015.06.005     Document Type: Article

References (59)

1. Ackerman M.E., Crispin M., Yu X., Baruah K., Boesch A.W., Harvey D.J., Alter G. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 2013, 123(5):2183. 10.1172/JCI65708.
2. Albert H., Collin M., Dudziak D., Ravetch J.V., Nimmerjahn F. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(39):15005. 10.1073/pnas.0808248105.
3. Anumula K.R. Quantitative glycan profiling of normal human plasma derived immunoglobulin and its fragments Fab and Fc. J. Immunol. Methods 2012, 382(1-2):167. 10.1016/j.jim.2012.05.022.
4. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25:21. 10.1146/annurev.immunol.25.022106.141702.
5. Bakovic M.P., Selman M.H., Hoffmann M., Rudan I., Campbell H., Deelder A.M., Wuhrer M. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J. Proteome Res. 2013, 12(2):821. 10.1021/pr300887z.
6. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., Michael N.L. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482(7383):89. 10.1038/nature10766.
7. Benhnia M.R., Maybeno M., Blum D., Aguilar-Sino R., Matho M., Meng X., Crotty S. Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. J. Virol. 2013, 87(3):1569. 10.1128/JVI.02152-12.
8. Boesch A.W., Brown E.P., Cheng H.D., Ofori M.O., Normandin E., Nigrovic P.A., Ackerman M.E. Highly parallel characterization of IgG Fc binding interactions. MAbs 2014, 6(4):915. 10.4161/mabs.28808.
9. Bournazos S., Chow S.K., Abboud N., Casadevall A., Ravetch J.V. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J. Clin. Invest. 2014, 124(2):725. 10.1172/JCI72676.
10. Brown E.P., Licht A.F., Dugast A.S., Choi I., Bailey-Kellogg C., Alter G., Ackerman M.E. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J. Immunol. Methods 2012, 386(1-2):117. 10.1016/j.jim.2012.09.007.
11. Collin M., Killian M. Bacterial modulation of Fc effector functions. Antibody Fc: Linking Adaptive and Innate Immunity 2014, 317. Elsevier Inc. M.E. Ackerman, F. Nimmerjahn (Eds.).
12. Collin M., Olsen A. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J. 2001, 20(12):3046. 10.1093/emboj/20.12.3046.
13. Collin M., Shannon O., Bjorck L. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(11):4265. 10.1073/pnas.0711271105.
14. DiLillo D.J., Tan G.S., Palese P., Ravetch J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc gamma R interactions for protection against influenza virus in vivo. Nat. Med. 2014, 20(2):143. 10.1038/nm.3443.
15. Espy C., Morelle W., Kavian N., Grange P., Goulvestre C., Viallon V., Guilpain P. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's). Arthritis Rheum. 2011, 63(7):2105. 10.1002/art.30362.
16. Ferrara C., Grau S., Jager C., Sondermann P., Brunker P., Waldhauer I., Benz J. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(31):12669. 10.1073/pnas.1108455108.
17. Fourati S., Vaccari M., Gordon S.N., Schifanella L., Cameron M., Keele B.F., Franchini G. Modulation of RAS pathways as a biomarker of protection against HIV and as a means to improve vaccine efficacy. AIDS Res. Hum. Retrovir. 2014, 30:A99.
18. Furness A.J., Vargas F.A., Peggs K.S., Quezada S.A. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol. 2014, 35(7):290. 10.1016/j.it.2014.05.002.
19. Gasdaska J.R., Sherwood S., Regan J.T., Dickey L.F. An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. Mol. Immunol. 2012, 50(3):134. 10.1016/j.molimm.2012.01.001.
20. Guo N., Liu Y., Masuda Y., Kawagoe M., Ueno Y., Kameda T., Sugiyama T. Repeated immunization induces the increase in fucose content on antigen-specific IgG N-linked oligosaccharides. Clin. Biochem. 2005, 38(2):149. 10.1016/j.clinbiochem.2004.10.002.
21. Halper-Stromberg A., Lu C.L., Klein F., Horwitz J.A., Bournazos S., Nogueira L., Nussenzweig M.C. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014, 158(5):989. 10.1016/j.cell.2014.07.043.
22. Hess C., Winkler A., Lorenz A.K., Holecska V., Blanchard V., Eiglmeier S., Ehlers M. T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J. Clin. Invest. 2013, 123(9):3788. 10.1172/JCI65938.
23. Huhn C., Selman M.H., Ruhaak L.R., Deelder A.M., Wuhrer M. IgG glycosylation analysis. Proteomics 2009, 9(4):882. 10.1002/pmic.200800715.
24. Jefferis R. The glycosylation of antibody molecules: functional significance. Glycoconj. J. 1993, 10(5):358.
25. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci. 2009, 30(7):356. 10.1016/j.tips.2009.04.007.
26. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 2012, 526(2):159. 10.1016/j.abb.2012.03.021.
27. Junttila T.T., Parsons K., Olsson C., Lu Y., Xin Y., Theriault J., Sliwkowski M.X. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 2010, 70(11):4481. 10.1158/0008-5472.can-09-3704.
28. Kapur R., Della Valle L., Sonneveld M., Hipgrave Ederveen A., Visser R., Ligthart P., Vidarsson G. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. Br. J. Haematol. 2014, 166(6):936. 10.1111/bjh.12965.
29. Kapur R., Kustiawan I., Vestrheim A., Koeleman C.A., Visser R., Einarsdottir H.K., Vidarsson G. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 2014, 123(4):471. 10.1182/blood-2013-09-527978.
30. Kodar K., Stadlmann J., Klaamas K., Sergeyev B., Kurtenkov O. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj. J. 2012, 29(1):57. 10.1007/s10719-011-9364-z.
31. Lundstrom S.L., Fernandes-Cerqueira C., Ytterberg A.J., Ossipova E., Hensvold A.H., Jakobsson P.J., Zubarev R.A. IgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a fab-Peptide sequence. PLoS ONE 2014, 9(11):e113924. 10.1371/journal.pone.0113924.
32. Mahan A.E., Tedesco J., Dionne K., Baruah K., Cheng H.D., De Jager P.L., Alter G. A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis. J. Immunol. Methods 2015, 417:34-44.
33. Mehta A.S., Long R.E., Comunale M.A., Wang M., Rodemich L., Krakover J., Block T.M. Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J. Virol. 2008, 82(3):1259. 10.1128/JVI.01600-07.
34. Melmer M., Stangler T., Premstaller A., Lindner W. Comparison of hydrophilic-interaction, reversed-phase and porous graphitic carbon chromatography for glycan analysis. J. Chromatogr. A 2011, 1218(1):118. 10.1016/j.chroma.2010.10.122.
35. Mimura Y., Ashton P.R., Takahashi N., Harvey D.J., Jefferis R. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. J. Immunol. Methods 2007, 326(1-2):116. 10.1016/j.jim.2007.07.014.
36. Moore J.S., Wu X., Kulhavy R., Tomana M., Novak J., Moldoveanu Z., Mestecky J. Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS 2005, 19(4):381.
37. Oefner C.M., Winkler A., Hess C., Lorenz A.K., Holecska V., Huxdorf M., Ehlers M. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J. Allergy Clin. Immunol. 2012, 129(6):1647. (e1613). 10.1016/j.jaci.2012.02.037.
38. Parekh R.B., Dwek R.A., Sutton B.J., Fernandes D.L., Leung A., Stanworth D., et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985, 316(6027):452.
39. Parekh R.B., Roitt I.M., Isenberg D.A., Dwek R.A., Ansell B.M., Rademacher T.W. Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet 1988, 1(8592):966.
40. Parekh R., Isenberg D., Rook G., Roitt I., Dwek R., Rademacher T. A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J. Autoimmun. 1989, 2(2):101.
41. Pincetic A., Bournazos S., DiLillo D.J., Maamary J., Wang T.T., Dahan R., Ravetch J.V. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 2014, 15(8):707. 10.1038/ni.2939.
42. Raju T.S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 2008, 20(4):471. 10.1016/j.coi.2008.06.007.
43. Ritamo I., Cloutier M., Valmu L., Neron S., Rabina J. Comparison of the glycosylation of in vitro generated polyclonal human IgG and therapeutic immunoglobulins. Mol. Immunol. 2014, 57(2):255. 10.1016/j.molimm.2013.10.005.
44. Rombouts Y., Ewing E., van de Stadt L.A., Selman M.H., Trouw L.A., Deelder A.M., Scherer H.U. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann. Rheum. Dis. 2015, 74(1):234. 10.1136/annrheumdis-2013-203565.
45. Rombouts Y., Willemze A., van Beers J.J., Shi J., Kerkman P.F., van Toorn L., Toes R.E. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann. Rheum. Dis. 2015, 10.1136/annrheumdis-2014-206598.
46. Ruhaak L.R., Huhn C., Waterreus W.J., de Boer A.R., Neususs C., Hokke C.H., Wuhrer M. Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins. Anal. Chem. 2008, 80(15):6119. 10.1021/ac800630x.
47. Saldova R., Royle L., Radcliffe C.M., Abd Hamid U.M., Evans R., Arnold J.N., Rudd P.M. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007, 17(12):1344. 10.1093/glycob/cwm100.
48. Scherer H.U., van der Woude D., Ioan-Facsinay A., el Bannoudi H., Trouw L.A., Wang J., Toes R.E. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 2010, 62(6):1620. 10.1002/art.27414.
49. Selman M.H., Niks E.H., Titulaer M.J., Verschuuren J.J., Wuhrer M., Deelder A.M. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J. Proteome Res. 2011, 10(1):143. 10.1021/pr1004373.
50. Selman M.H., de Jong S.E., Soonawala D., Kroon F.P., Adegnika A.A., Deelder A.M., Wuhrer M. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol. Cell Proteomics 2012, 11(4). (M111 014563). 10.1074/mcp.M111.014563.
51. Song R., Oren D.A., Franco D., Seaman M.S., Ho D.D. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity. Nat. Biotechnol. 2013, 31(11):1047. 10.1038/nbt.2677.
52. von Pawel-Rammingen U., Johansson B.P., Bjorck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 2002, 21(7):1607. 10.1093/emboj/21.7.1607.
53. Wang J., Balog C.I.A., Stavenhagen K., Koeleman C.A.M., Scherer H.U., Selman M.H.J., Wuhrer M. Fc-glycosylation of IgG1 is modulated by B-cell stimul. Molecular & cellular proteomics 2011, 10(5). (M110.004655-M004110.004655). 10.1074/mcp.M110.004655.
54. Wang J.R., Guan W.D., Yau L.F., Gao W.N., Zhan Y.Q., Liu L., Jiang Z.H. Glycomic signatures on serum IgGs for prediction of postvaccination response. Sci. Rep. 2015, 5:7648. 10.1038/srep07648.
55. Wilson J.A., Hevey M., Bakken R., Guest S., Bray M., Schmaljohn A.L., Hart M.K. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000, 287(5458):1664.
56. Winkler A., Berger M., Ehlers M. Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodies. F1000Res 2013, 2:169. 10.12688/f1000research.2-169.v1.
57. Wuhrer M., Porcelijn L., Kapur R., Koeleman C.A., Deelder A., de Haas M., Vidarsson G. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J. Proteome Res. 2009, 8(2):450. 10.1021/pr800651j.
58. Wuhrer M., Stavenhagen K., Koeleman C.A., Selman M.H., Harper L., Jacobs B., Morgan M.D. Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1 autoantibodies from granulomatosis with polyangiitis patients feature show low levels of bisection, galactosylation and sialylation. J. Proteome Res. 2015, 10.1021/pr500780a.
59. Zeitlin L., Pettitt J., Scully C., Bohorova N., Kim D., Pauly M., Olinger G.G. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(51):20690. 10.1073/pnas.1108360108.